Loading
NASDAQHealthcareBiotechnology
Latest quote
$12.725
+$0.045 · +0.35%
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Previous close
$12.725
+$0.045 · +0.35%
After-hours
$12.725
$0.00 · 0.00%
Sep 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Day range
Current $12.725
52-week range
Current $12.725
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
25
Expensive
Sentiment
49
Mixed
Risk
47
Elevated Risk
Momentum
54
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Day range
Current $12.725
52-week range
Current $12.725
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | 75K USD | 73K USD | 59K USD |
| Cost of goods sold | 396K USD | 343K USD | — | 9K USD | 123K USD |
| Gross profit | −396K USD | −343K USD | 75K USD | 64K USD | −64K USD |
| Research and development | 18.33M USD | 15.61M USD | 12.77M USD | 11.27M USD | 7.02M USD |
| Selling, general, and administrative | 23.43M USD | 6.99M USD | 6.38M USD | 6.65M USD | 6.51M USD |
| Operating expenses | 41.77M USD | 22.49M USD | 19.16M USD | 17.92M USD | 13.53M USD |
| Interest income | — | 904K USD | — | — | — |
| Interest expense | −3.29M USD | — | 33K USD | 32K USD | 6K USD |
| Depreciation and amortization | 396K USD | 343K USD | 381K USD | 392K USD | 424K USD |
| Operating income | −41.77M USD | −22.49M USD | −19.08M USD | −17.85M USD | −13.6M USD |
| Net income | −37.92M USD | −21.75M USD | −19.56M USD | −18.21M USD | −13.88M USD |
Company facts updated Sep 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$20.50
61.10% upside| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jun 1, 2018 | $0.003Irregular | Jun 4, 2018 | Jun 8, 2018 |
Ex-dividend Jun 1, 2018
$0.003
Irregular
Record Jun 4, 2018 · Payment Jun 8, 2018
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
